878 related articles for article (PubMed ID: 27001570)
1. Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency.
Bouffet E; Larouche V; Campbell BB; Merico D; de Borja R; Aronson M; Durno C; Krueger J; Cabric V; Ramaswamy V; Zhukova N; Mason G; Farah R; Afzal S; Yalon M; Rechavi G; Magimairajan V; Walsh MF; Constantini S; Dvir R; Elhasid R; Reddy A; Osborn M; Sullivan M; Hansford J; Dodgshun A; Klauber-Demore N; Peterson L; Patel S; Lindhorst S; Atkinson J; Cohen Z; Laframboise R; Dirks P; Taylor M; Malkin D; Albrecht S; Dudley RW; Jabado N; Hawkins CE; Shlien A; Tabori U
J Clin Oncol; 2016 Jul; 34(19):2206-11. PubMed ID: 27001570
[TBL] [Abstract][Full Text] [Related]
2. Durable Response to Nivolumab in a Pediatric Patient with Refractory Glioblastoma and Constitutional Biallelic Mismatch Repair Deficiency.
AlHarbi M; Ali Mobark N; AlMubarak L; Aljelaify R; AlSaeed M; Almutairi A; Alqubaishi F; Hussain ME; Balbaid AAO; Said Marie A; AlSubaie L; AlShieban S; alTassan N; Ramkissoon SH; Abedalthagafi M
Oncologist; 2018 Dec; 23(12):1401-1406. PubMed ID: 30104292
[TBL] [Abstract][Full Text] [Related]
3. High frequency of mismatch repair deficiency among pediatric high grade gliomas in Jordan.
Amayiri N; Tabori U; Campbell B; Bakry D; Aronson M; Durno C; Rakopoulos P; Malkin D; Qaddoumi I; Musharbash A; Swaidan M; Bouffet E; Hawkins C; Al-Hussaini M;
Int J Cancer; 2016 Jan; 138(2):380-5. PubMed ID: 26293621
[TBL] [Abstract][Full Text] [Related]
4. Gastrointestinal Findings in the Largest Series of Patients With Hereditary Biallelic Mismatch Repair Deficiency Syndrome: Report from the International Consortium.
Aronson M; Gallinger S; Cohen Z; Cohen S; Dvir R; Elhasid R; Baris HN; Kariv R; Druker H; Chan H; Ling SC; Kortan P; Holter S; Semotiuk K; Malkin D; Farah R; Sayad A; Heald B; Kalady MF; Penney LS; Rideout AL; Rashid M; Hasadsri L; Pichurin P; Riegert-Johnson D; Campbell B; Bakry D; Al-Rimawi H; Alharbi QK; Alharbi M; Shamvil A; Tabori U; Durno C
Am J Gastroenterol; 2016 Feb; 111(2):275-84. PubMed ID: 26729549
[TBL] [Abstract][Full Text] [Related]
5. Effective Immunotherapy of Glioblastoma in an Adolescent with Constitutional Mismatch Repair-Deficiency Syndrome.
Pavelka Z; Zitterbart K; Nosková H; Bajčiová V; Slabý O; Štěrba J
Klin Onkol; 2019; 32(1):70-74. PubMed ID: 30764633
[TBL] [Abstract][Full Text] [Related]
6. Lynch syndrome-associated ultra-hypermutated pediatric glioblastoma mimicking a constitutional mismatch repair deficiency syndrome.
Yang C; Austin F; Richard H; Idowu M; Williamson V; Sabato F; Ferreira-Gonzalez A; Turner SA
Cold Spring Harb Mol Case Stud; 2019 Oct; 5(5):. PubMed ID: 31604779
[TBL] [Abstract][Full Text] [Related]
7. Investigation of the relationship between immune checkpoints and mismatch repair deficiency in recurrent and nonrecurrent glioblastoma.
Çakır E; Saygın İ; Ercin ME
Turk J Med Sci; 2021 Aug; 51(4):1800-1808. PubMed ID: 33600097
[TBL] [Abstract][Full Text] [Related]
8. Recommendations on Surveillance and Management of Biallelic Mismatch Repair Deficiency (BMMRD) Syndrome: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer.
Durno C; Boland CR; Cohen S; Dominitz JA; Giardiello FM; Johnson DA; Kaltenbach T; Levin TR; Lieberman D; Robertson DJ; Rex DK
Gastroenterology; 2017 May; 152(6):1605-1614. PubMed ID: 28363489
[TBL] [Abstract][Full Text] [Related]
9. Immune Checkpoint Inhibition Is Effective in Hypermutant Glioblastoma.
Cancer Discov; 2016 May; 6(5):OF7. PubMed ID: 27034383
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy holds the key to cancer treatment and prevention in constitutional mismatch repair deficiency (CMMRD) syndrome.
Westdorp H; Kolders S; Hoogerbrugge N; de Vries IJM; Jongmans MCJ; Schreibelt G
Cancer Lett; 2017 Sep; 403():159-164. PubMed ID: 28645564
[TBL] [Abstract][Full Text] [Related]
11. Molecular Profiling of Pediatric and Adult Glioblastoma.
Gestrich CK; Jajosky AN; Elliott R; Stearns D; Sadri N; Cohen ML; Couce ME
Am J Clin Pathol; 2021 Mar; 155(4):606-614. PubMed ID: 33210143
[TBL] [Abstract][Full Text] [Related]
12. High tumor mutational burden and T-cell activation are associated with long-term response to anti-PD1 therapy in Lynch syndrome recurrent glioblastoma patient.
Anghileri E; Di Ianni N; Paterra R; Langella T; Zhao J; Eoli M; Patanè M; Pollo B; Cuccarini V; Iavarone A; Rabadan R; Finocchiaro G; Pellegatta S
Cancer Immunol Immunother; 2021 Mar; 70(3):831-842. PubMed ID: 33140187
[TBL] [Abstract][Full Text] [Related]
13. Management of Acute Myeloblastic Leukemia in a Child With Biallelic Mismatch Repair Deficiency.
Elhasid R; Dvir R; Rosenfeld Keidar H; Ben Shachar S; Bitan M; Solar I; Durno C; Aronson M; Malkin D; Hawkins C; Bouffet E; Tabori U;
J Pediatr Hematol Oncol; 2015 Nov; 37(8):e490-3. PubMed ID: 26274037
[TBL] [Abstract][Full Text] [Related]
14. Sustained complete response of recurrent glioblastoma to combined checkpoint inhibition in a young patient with constitutional mismatch repair deficiency.
Larouche V; Atkinson J; Albrecht S; Laframboise R; Jabado N; Tabori U; Bouffet E;
Pediatr Blood Cancer; 2018 Dec; 65(12):e27389. PubMed ID: 30160041
[No Abstract] [Full Text] [Related]
15. Germline PMS2 and somatic POLE exonuclease mutations cause hypermutability of the leading DNA strand in biallelic mismatch repair deficiency syndrome brain tumours.
Andrianova MA; Chetan GK; Sibin MK; Mckee T; Merkler D; Narasinga RK; Ribaux P; Blouin JL; Makrythanasis P; Seplyarskiy VB; Antonarakis SE; Nikolaev SI
J Pathol; 2017 Nov; 243(3):331-341. PubMed ID: 28805995
[TBL] [Abstract][Full Text] [Related]
16. Recommendations on Surveillance and Management of Biallelic Mismatch Repair Deficiency (BMMRD) Syndrome: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer.
Durno C; Boland CR; Cohen S; Dominitz JA; Giardiello FM; Johnson DA; Kaltenbach T; Levin TR; Lieberman D; Robertson DJ; Rex DK
Am J Gastroenterol; 2017 May; 112(5):682-690. PubMed ID: 28349994
[TBL] [Abstract][Full Text] [Related]
17. Recommendations on surveillance and management of biallelic mismatch repair deficiency (BMMRD) syndrome: a consensus statement by the US Multi-Society Task Force on Colorectal Cancer.
Durno C; Boland CR; Cohen S; Dominitz JA; Giardiello FM; Johnson DA; Kaltenbach T; Levin TR; Lieberman D; Robertson DJ; Rex DK
Gastrointest Endosc; 2017 May; 85(5):873-882. PubMed ID: 28363411
[No Abstract] [Full Text] [Related]
18. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
Le DT; Durham JN; Smith KN; Wang H; Bartlett BR; Aulakh LK; Lu S; Kemberling H; Wilt C; Luber BS; Wong F; Azad NS; Rucki AA; Laheru D; Donehower R; Zaheer A; Fisher GA; Crocenzi TS; Lee JJ; Greten TF; Duffy AG; Ciombor KK; Eyring AD; Lam BH; Joe A; Kang SP; Holdhoff M; Danilova L; Cope L; Meyer C; Zhou S; Goldberg RM; Armstrong DK; Bever KM; Fader AN; Taube J; Housseau F; Spetzler D; Xiao N; Pardoll DM; Papadopoulos N; Kinzler KW; Eshleman JR; Vogelstein B; Anders RA; Diaz LA
Science; 2017 Jul; 357(6349):409-413. PubMed ID: 28596308
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of PD-1 blockade in tumors with MMR deficiency.
Lee V; Le DT
Immunotherapy; 2016; 8(1):1-3. PubMed ID: 26643016
[No Abstract] [Full Text] [Related]
20. Hypermutated Tumors and Immune Checkpoint Inhibition.
Ciombor KK; Goldberg RM
Drugs; 2018 Feb; 78(2):155-162. PubMed ID: 29350327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
